Neuroscience disorders represent a sizable unmet therapeutic need, but long development timelines and low chances of success have caused biopharma companies to cut investment in this arena. Now a better understanding of disease biology and a willingness to access expertise through partnerships have brought about a resurgence in neuroscience R&D. The fruits of this resurgence can’t come too soon. With central nervous system disorders on the rise as populations age — dementia rates are expected to quadruple by 2050 — there is a dire need for new drugs.
On June 16 during the BIO International Convention, WuXi’s SVP of International Discovery Service Unit, Dr. Richard Soll, will host a panel session “The Revitalization of Neuroscience R&D” to discuss new trends in neuroscience R&D and their implications for patients and society. The panelists include Kees Been, Founder, President and CEO of Lysosomal Therapeutics Inc.; Steve Kanes, CMO of Sage Therapeutics; Gerhard Koenig, SVP of Research and CSO of Forum Pharmaceuticals; and Todd Sherer, CEO of The Michael J. Fox Foundation.
The BIO International Convention, to be held in Philadelphia June 15 – 18, attracts more than 15,000 scientists, biotech leaders and entrepreneurs to provide insights and inspirations on major trends in the industry. For more information about this session, visit https://mybio.org/event/member/162827.
WuXi’s VP of Corporate Alliances, Dr. Hui Cai, will host another panel session at BIO called “Demystifying Product Development and Market Access in China and Asia”. Click here to read more about it.